Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine

References

• Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, et al, Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375:1969 - 87; http://dx.doi.org/10.1016/S0140-6736(10)60549-1; PMID: 20466419
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893 - 902; http://dx.doi.org/10.1016/S0140-6736(09)61204-6; PMID: 19748398
   PubMed Web of Science ®Google Scholar
• Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002; 2:25 - 32; http://dx.doi.org/10.1016/S1473-3099(01)00170-0; PMID: 11892493
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010; 16:217 - 25; PMID: 20375783
   PubMed Web of Science ®Google Scholar
• Improving Global Health by Preventing Pneumococcal Disease [Internet]. All-Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World; 2008.Available from http://www.path.org/vaccineresources/details.php?i=692
   Google Scholar
• Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:RR-11 1 - 18; PMID: 21150868
   PubMedGoogle Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962 - 73; http://dx.doi.org/10.1016/S0140-6736(10)62225-8; PMID: 21492929
   PubMed Web of Science ®Google Scholar
• Blum MD, Dagan R, Mendelman PM, Pinsk V, Giordani M, Li S, Bohidar N, McNeely TB. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000; 18:2359 - 67; http://dx.doi.org/10.1016/S0264-410X(00)00021-9; PMID: 10738092
   PubMed Web of Science ®Google Scholar
• Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997; 16:1053 - 9; http://dx.doi.org/10.1097/00006454-199711000-00010; PMID: 9384339
   PubMed Web of Science ®Google Scholar
• Russell FM, Balloch A, Licciardi PV, Carapetis JR, Tikoduadua L, Waqatakirewa L, Cheung YB, Mulholland EK, Tang ML. Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine 2011; 29:4499 - 506; http://dx.doi.org/10.1016/j.vaccine.2011.04.038; PMID: 21539882
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Burton RL, Lin J, Licciardi PV, Balloch A, Tikoduadua L, Waqatakirewa L, Cheung YB, Tang ML, et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2011; 29:535 - 44; http://dx.doi.org/10.1016/j.vaccine.2010.10.046; PMID: 21044669
   PubMed Web of Science ®Google Scholar
• Russell FM, Licciardi PV, Balloch A, Biaukula V, Tikoduadua L, Carapetis JR, Nelson J, Jenney AW, Waqatakirewa L, Colquhoun S, et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 2010; 28:3086 - 94; http://dx.doi.org/10.1016/j.vaccine.2010.02.065; PMID: 20199764
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Vaccines to prevent pneumococcal disease. Resolution No. 02/13-1, 2013. Available from: http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/02-13-1-pneumo.pdf
   Google Scholar
• Ahman H, Käyhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998; 17:211 - 6; http://dx.doi.org/10.1097/00006454-199803000-00008; PMID: 9535248
   PubMed Web of Science ®Google Scholar
• Choo S, Seymour L, Morris R, Quataert S, Lockhart S, Cartwright K, Finn A. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J 2000; 19:854 - 62; http://dx.doi.org/10.1097/00006454-200009000-00009; PMID: 11001109
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, Crowley-Luke A, Andrews N, Morris R, Borrow R, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006; 25:312 - 9; http://dx.doi.org/10.1097/01.inf.0000207483.60267.e7; PMID: 16567982
   PubMed Web of Science ®Google Scholar
• Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine. Vaccine 2004; 22:2696 - 700; http://dx.doi.org/10.1016/j.vaccine.2003.03.001; PMID: 15246599
   PubMed Web of Science ®Google Scholar
• Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M, Hovi T, Eskola J, et al, Finnish Otitis Media Study Group. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003; 37:1155 - 64; http://dx.doi.org/10.1086/378744; PMID: 14557958
   PubMed Web of Science ®Google Scholar
• Bogaert D, Hermans PW, Adrian PV, Rümke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004; 22:2209 - 20; http://dx.doi.org/10.1016/j.vaccine.2003.11.038; PMID: 15149779
   PubMed Web of Science ®Google Scholar
• Schuerman L, Wysocki J, Tejedor JC, Knuf M, Kim KH, Poolman J. Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol 2011; 18:2161 - 7; http://dx.doi.org/10.1128/CVI.05313-11; PMID: 21994351
   PubMedGoogle Scholar
• Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006; 13:165 - 9; http://dx.doi.org/10.1128/CVI.13.2.165-169.2006; PMID: 16467321
   PubMed Web of Science ®Google Scholar
• Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009; 16:376 - 81; http://dx.doi.org/10.1128/CVI.00344-08; PMID: 19144787
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?. BMC Pediatr 2010; 10:4; http://dx.doi.org/10.1186/1471-2431-10-4; PMID: 20122261
   PubMed Web of Science ®Google Scholar
• Phongsamart W, Srifeungfung S, Dejsirilert S, Chatsuwan T, Nunthapisud P, Treerauthaweeraphong V, Rungnobhakhun P, Chokephaibulkit K. Serotype distribution and antimicrobial susceptibility of S. pneumoniae causing invasive disease in Thai children younger than 5 years old, 2000-2005. Vaccine 2007; 25:1275 - 80; http://dx.doi.org/10.1016/j.vaccine.2006.10.001; PMID: 17092618
   PubMed Web of Science ®Google Scholar
• Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis 2006; 42:907 - 14; http://dx.doi.org/10.1086/500941; PMID: 16511752
   PubMed Web of Science ®Google Scholar
• Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46:174 - 82; http://dx.doi.org/10.1086/524660; PMID: 18171247
   PubMed Web of Science ®Google Scholar
• Srifeungfung S, Tribuddharat C, Comerungsee S, Chatsuwan T, Treerauthanaweeraphong V, Rungnobhakhun P, Nunthapisud P, Chokephaibulkit K. Serotype coverage of pneumococcal conjugate vaccine and drug susceptibility of Streptococcus pneumoniae isolated from invasive or non-invasive diseases in central Thailand, 2006-2009. Vaccine 2010; 28:3440 - 4; http://dx.doi.org/10.1016/j.vaccine.2010.02.071; PMID: 20199759
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Expert Committee on Biological Standardization 54th report ed. Geneva: World Health Organization, 2005.
   Google Scholar
• Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol 2010; 17:134 - 42; http://dx.doi.org/10.1128/CVI.00289-09; PMID: 19889940
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25:3816 - 26; http://dx.doi.org/10.1016/j.vaccine.2007.01.119; PMID: 17368878
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis 2011; 15:e249 - 56; http://dx.doi.org/10.1016/j.ijid.2010.12.004; PMID: 21334243
   PubMed Web of Science ®Google Scholar
• Plikaytis BD, Goldblatt D, Frasch CE, Blondeau C, Bybel MJ, Giebink GS, Jonsdottir I, Käyhty H, Konradsen HB, Madore DV, et al. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 2000; 38:2043 - 50; PMID: 10834951
   PubMed Web of Science ®Google Scholar
• Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266 - 72; PMID: 11238206
   PubMedGoogle Scholar
• WHO Publication. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012; 30:4717 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.04.093; PMID: 22621828
   PubMed Web of Science ®Google Scholar
• Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006; 13:1004 - 9; http://dx.doi.org/10.1128/CVI.00112-06; PMID: 16960111
   PubMed Web of Science ®Google Scholar